Ken Garber

Learn More
  • Ken Garber
  • 2006
Mich., " and the opinions are driven by suggestive but not conclusive science. " Still the Standard Both the orthotopic and transgenic camps can muster strong theoretical arguments for their respective models. But for all their faults, subcutaneous xeno-grafts remain the standard for cancer drug screening in the pharmaceutical industry. These models are(More)
  • Ken Garber
  • 2010
I t's hard to imagine two diseases more different than Parkinson's and cancer. Parkinson's disease, a progressive neuro-logical disease that causes tremors, muscular rigidity, and loss of motor function, happens when neurons that release the neu-rotransmitter dopamine die in the tiny substantia nigra region of the brain. In cancer , cell death fails to(More)
A metaphor for cancer is normal development gone awry. All tissues in the body arise from embry-onic stem cells that gradually give rise to specialized cells. Cancer resembles a case of arrested development because less differentiated tumors are almost always the most aggressive. So it's no surprise that genes regulating normal fetal and childhood(More)
D evelopmental pathways have become important targets for new cancer drugs. Three such pathways — Notch, Hedgehog , and Wnt — have been strongly implicated in cancer, and drug companies have targeted them all. Inhibitors of Notch and Hedgehog are already in clinical trials, including a Hedgehog inhibitor from Genentech that has shown early promise in(More)
  • Ken Garber
  • 2011
A utophagy, the process of " self-eating " within cells, has been controversial in cancer since it was first linked to the disease in 1999. Because autophagy can either suppress or promote tumors, depending on the context, the field has been marked by both confusion and unwillingness by drug companies to get involved in therapies. But that's changed. A(More)